Enzymotec Announces Publication Of Clinical Study Results On Crying Reduction Following Usage Of INFAT® In Infants

MIGDAL HA'EMEQ, Israel, July 7, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today on publication of its clinical study results evaluating the effect of INFAT® usage on crying in healthy infants (link to the journal: http://www.biomedcentral.com/1471-2431/14/152).

Help employers find you! Check out all the jobs and post your resume.